Fig. 1Proportion of statin-eligible subjects according to Adult Treatment Panel (ATP)-III and American College of Cardiology/American Heart Association (ACC/AHA) guidelines and renal function. eGFR, estimated glomerular filtration rate.
Table 1General Characteristics of the Participants
Characteristic |
Total (n=18,746) |
Male (n=15,015) |
Female (n=3,731) |
Age, yr |
46.0±5.9 |
45.6±5.5 |
47.5±7.2 |
Body mass index, kg/m2
|
24.4±3.0 |
24.8±2.8 |
23.0±3.1 |
Fasting glucose, mg/dL |
100.8±18.1 |
101.9±18.5 |
96.4±15.5 |
SBP, mm Hg |
114.0±12.6 |
115.3±12.2 |
109.0±13.2 |
DBP, mm Hg |
74.7±10.1 |
76.0±9.9 |
69.5±9.4 |
Total cholesterol, mg/dL |
205.0±33.4 |
205.8±33.4 |
201.5±33.4 |
Triglyceride, mg/dL |
141.3±86.8 |
151.0±90.3 |
102.4±56.7 |
HDL-C, mg/dL |
53.5±13.1 |
51.1±12.2 |
60.9±14.0 |
LDL-C, mg/dL |
131.6±30.9 |
133.0±30.7 |
126.0±31.1 |
Glycated hemoglobin, % |
5.8±0.6 |
5.8±0.6 |
5.8±0.6 |
Diabetes |
1,528 (8.2) |
1,309 (8.7) |
219 (5.9) |
Hypertension |
2,431 (13.0) |
2,091 (13.9) |
340 (9.1) |
Hyperlipidemic therapy |
979 (5.2) |
777 (5.2) |
202 (5.4) |
10-Year CHD risk according to FRS, % |
5.6±3.7 |
6.3±3.6 |
2.6±2.6 |
10-Year cardiovascular risk according to PCE, % |
1.3±0.7 |
1.3±0.7 |
1.1±0.4 |
eGFR, mL/min/1.73 m2
|
89.1±17.4 |
89.3±17.4 |
88.6±17.2 |
≥90 |
8,559 (45.7) |
6,863 (45.7) |
1,696 (45.5) |
60≤&<90 |
9,916 (52.9) |
7,969 (53.1) |
1,947 (52.2) |
<60 |
271 (1.4) |
183 (1.2) |
88 (2.4) |
Table 2Baseline Characteristics of Statin-Eligible Participants
Characteristic |
Statin-eligible by ATP-III guidelines |
Statin-eligible by ACC/AHA guidelines |
Total (n=3,546) |
Male (n=3,038) |
Female (n=508) |
Total (n=4,048) |
Male (n=3,461) |
Female (n=587) |
Age, yr |
48.4±7.1 |
47.7±6.4 |
53.0±8.8 |
49.6±8.0 |
48.9±7.5 |
54.0±9.7 |
Body mass index, kg/m2
|
25.5±3.0 |
25.6±2.9 |
24.6±3.5 |
25.4±3.1 |
25.5±2.9 |
24.4±3.5 |
Fasting glucose, mg/dL |
113.3±31.2 |
113.8±31.2 |
110.0±31.1 |
114.5±31.6 |
115.2±31.7 |
110.2±30.7 |
SBP, mm Hg |
117.9±13.7 |
118.4±13.4 |
114.9±15.0 |
118.0±13.2 |
118.5±12.9 |
115.2±14.9 |
DBP, mm Hg |
77.8±10.8 |
78.6±10.7 |
72.4±9.5 |
77.3±10.1 |
78.1±10.0 |
72.2±9.5 |
Total cholesterol, mg/dL |
225.4±40.6 |
225.9±39.9 |
222.2±45.0 |
216.8±43.4 |
216.9±43.0 |
216.0±45.8 |
Triglyceride, mg/dL |
172.0±94.5 |
178.5±97.1 |
133.4±64.3 |
179.3±115.6 |
187.4±120.1 |
131.6±67.0 |
HDL-C, mg/dL |
49.8±11.7 |
48.8±11.1 |
55.9±13.1 |
49.8±12.3 |
48.6±11.7 |
56.5±13.4 |
LDL-C, mg/dL |
151.4±38.2 |
152.0±37.0 |
147.7±44.1 |
141.6±41.0 |
141.6±40.4 |
141.2±44.6 |
Glycated hemoglobin, % |
6.2±1.0 |
6.2±1.0 |
6.4±1.1 |
6.3±1.0 |
6.2±1.0 |
6.4±1.1 |
Diabetes |
1,242 (35.0) |
1,061 (34.9) |
181 (35.6) |
1,528 (37.7) |
1,309 (37.8) |
219 (37.3) |
Hypertension |
881 (24.8) |
777 (25.6) |
104 (20.5) |
895 (22.1) |
778 (22.5) |
117 (19.9) |
Hyperlipidemic therapy |
979 (27.6) |
777 (25.6) |
202 (39.8) |
979 (24.2) |
777 (22.5) |
202 (34.4) |
10-Year CHD risk according to FRS, % |
9.5±5.2 |
10.1±5.1 |
5.6±4.2 |
9.1±5.2 |
9.8±5.1 |
5.4±3.9 |
10-Year cardiovascular risk according to PCE, % |
1.9±1.0 |
1.9±1.0 |
1.3±0.7 |
1.9±1.0 |
2.0±1.0 |
1.4±0.8 |
eGFR, mL/min/1.73 m2
|
88.3±19.1 |
88.9±18.9 |
84.7±20.1 |
88.1±19.5 |
88.7±19.2 |
84.6±20.5 |
≥90 |
1,498 (42.2) |
1,328 (43.7) |
170 (33.5) |
1,684 (41.6) |
1,484 (42.9) |
200 (34.1) |
60≤&<90 |
1,953 (55.1) |
1,648 (54.2) |
305 (60.0) |
2,234 (55.2) |
1,891 (54.6) |
343 (58.4) |
<60 |
95 (2.7) |
62 (2.0) |
33 (6.5) |
130 (3.2) |
86 (2.5) |
44 (7.5) |
Table 3Concordance of Guideline Recommendations for Statin Therapya
|
κ value |
KDIGO-ATP III |
0.531b
|
KDIGO-ACC/AHA |
0.689b
|
Table 4Comparison of the 10-Year Atherosclerotic Cardiovascular Disease Risk Analyzed by Two Different Risk Calculators
|
Renal function, mL/min/1.73 m2
|
P valuea
|
eGFR ≥90 |
60≤eGFR<90 |
eGFR <60 |
FRS |
5.4±3.6 |
5.7±3.8 |
7.8±5.7 |
<0.001 |
PCE |
1.3±0.6 |
1.3±0.7 |
1.9±1.2 |
<0.001 |